 Severe toxicity secondary dehydrogenase deficiency common pharmacogenetic syndrome study inheritance defect pyrimidine catabolism association drug-induced toxicity patient FUra adjuvant chemotherapy breast carcinoma study population affected patient proband blood relatives healthy volunteers activity dihydropyrimidine dehydrogenase DPD initial enzyme pyrimidine FUra catabolism peripheral blood mononuclear cells subject specific radiometric assay FUra substrate proband detectable DPD activity enzyme levels proband relatives controls autosomal recessive pattern inheritance third patient severe FUra toxicity secondary alteration pyrimidine catabolism second clinic population frequency genetic defect DPD activity important management patients severe toxicity secondary FUra chemotherapy